Sponsor content
176 result(s) found, displaying 51 to 60
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 2.4 mg semaglutide 3.2 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 0.25 mg semaglutide 0.5 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
Prescription medicine decision summaryAlhemo (concizumab) is approved to prevent haemophilia.
-
Prescription medicine registrationActive ingredients: somapacitan.
-
Prescription medicine registrationActive ingredients: concizumab.
-
Prescription medicine decision summaryTGA decision: Alhemo is approved where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B.
-
Prescription medicine registrationActive ingredients: concizumab.
-
Prescription medicine decision summaryTGA decision: Esperoct (turoctocog alfa pegol) is approved to treat haemophilia A.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOGROYA somapacitan 10 mg (6.7 mg/mL) solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBELSUS semaglutide 7 mg tablet blister pack.